Genprex (NASDAQ:GNPX) Stock Price Up 8.1% – Time to Buy?

Genprex (NASDAQ:GNPX)’s stock price shot up 8.1% on Friday . The stock traded as high as $2.85 and last traded at $2.66. 1,949,799 shares changed hands during mid-day trading, an increase of 28% from the average session volume of 1,518,983 shares. The stock had previously closed at $2.46.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Thursday, January 22nd. Wall Street Zen upgraded Genprex to a “sell” rating in a research report on Saturday, October 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Genprex Stock Up 8.1%

The company has a market capitalization of $8.30 million, a P/E ratio of -0.10 and a beta of -0.81. The company has a 50-day moving average of $2.52 and a two-hundred day moving average of $7.53.

Genprex (NASDAQ:GNPX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($5.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($12.50) by $7.50. As a group, equities analysts expect that Genprex will post -5.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP increased its holdings in shares of Genprex (NASDAQ:GNPX) by 11.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the period. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.